Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Nutex To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK Â , Sept. ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex- ...

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds investors who purchased Nutex Health Inc. ("Nutex†or the "Company†) (NASDAQ:NUTX) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your Nutex investments, you have until October 21, 2025 to request lead plaintiff appointment. Follow the l. ...

Core Viewpoint - Nutex Health Inc. is facing legal challenges due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2][9]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, with thousands of questionable claims submitted to extract outsized reimbursements [2][3]. - The lawsuit asserts that Nutex's revenue model is unstable and that financial statements did not accurately reflect the company's operations [2]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital, which accused HaloMD of a fraudulent scheme, Nutex's stock dropped over 10% [3][4]. - After Nutex announced a delay in its Form 10-Q filing, shares plunged 16.39%, closing at $92.91 [6]. Group 3: Financial Reporting Issues - Nutex is accused of misrepresenting its internal control progress, particularly in misclassifying stock-based compensation obligations [5]. - The Audit Committee determined that prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, claiming public disclosures were materially misleading [9]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [10].

Core Viewpoint - Nutex Health Inc. is facing allegations of issuing materially false and misleading statements during the class period from August 8, 2024, to August 14, 2025, which has led to a class action lawsuit against the company [1]. Summary by Sections Allegations - The complaint alleges that Nutex Health engaged in a coordinated scheme to defraud insurance companies through its third-party vendor HaloMD, resulting in unsustainable revenues [1]. - The company overstated its ability to remediate material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [1]. - Nutex misclassified stock-based compensation obligations as equity instead of liabilities, increasing the risk of failing to file financial reports with the SEC on time [1]. - The allegations suggest that Nutex's business and financial prospects were overstated, making public statements materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of Nutex during the specified class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 21, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Nutex Health Inc. has appointed Wesley Bamburg as the Chief Operating Officer, effective October 13, 2025, to enhance its operational capabilities and support its growth strategy in the healthcare sector [1][5][6]. Company Overview - Nutex Health Inc. is a physician-led integrated healthcare delivery system with 24 micro hospitals and outpatient departments across 11 states, focusing on patient-centric healthcare [1][7]. - The company operates two divisions: a Hospital Division that manages innovative healthcare models and a Population Health Management Division that oversees provider networks [7][8]. Leadership Appointment - Wesley Bamburg brings 20 years of experience in healthcare operations and business development, having previously served as COO at HCA Houston Healthcare North Cypress and HCA Houston Healthcare Medical Center [2][3]. - Bamburg's background includes roles in payor contracting and network operations, providing him with a comprehensive understanding of both payor and provider perspectives [3][4]. Executive Statements - Bamburg expressed enthusiasm about joining Nutex Health, highlighting the company's innovative model and commitment to patient-centric care [5]. - The CEO, Dr. Tom Vo, and CFO, Jon Bates, emphasized Bamburg's extensive experience as a valuable asset for the company's growth and expansion efforts [5][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, including the involvement of HaloMD in fraudulent arbitration results [4]. - It is claimed that Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [4]. - The allegations suggest that these misrepresentations inflated Nutex's business and financial prospects, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 21, 2025 [4][10]. Group 1: Allegations Against Nutex - The complaint alleges that Nutex and its executives made false or misleading statements and failed to disclose critical information regarding their financial practices and internal controls [6]. - Specific allegations include that Nutex engaged in a fraudulent scheme with HaloMD to defraud insurance companies, leading to unsustainable revenue [6]. - The company is accused of overstating its ability to remediate weaknesses in its financial reporting controls, which resulted in improper accounting for stock-based compensation [6]. Group 2: Stock Price Impact - Following the release of a short report by Blue Orca Capital, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [8]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price dropped further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [9]. Group 3: Legal and Investor Actions - Investors who suffered losses exceeding $50,000 between August 8, 2024, and August 15, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Nutex's conduct [11].

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent conduct, leading to overstated business and financial prospects [2]. - The company reportedly overstated its remediation of material weaknesses in internal controls over financial reporting, affecting its ability to account for stock-based compensation obligations correctly [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation model [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 21, 2025 [1][3]. Group 1: Allegations Against Nutex - The complaint alleges that Nutex and its executives made false or misleading statements and failed to disclose critical information regarding their operations with HaloMD, which involved a fraudulent scheme to defraud insurance companies [3]. - Specific allegations include that Nutex's revenues from HaloMD were unsustainable due to fraudulent conduct, and the company overstated its ability to remediate internal control weaknesses over financial reporting [3]. - Nutex is accused of improperly calculating stock-based compensation obligations, which increased the risk of failing to file timely financial reports with the SEC [3]. Group 2: Stock Price Impact - Following the release of a short report by Blue Orca Capital, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [5]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price dropped further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [5]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [6]. - Faruqi & Faruqi encourages individuals with information regarding Nutex's conduct to come forward, including whistleblowers and former employees [7].